Litigation
Celgene Corp. v. Dr. Reddy's Laboratories, Ltd. et al.
consent judgment2:19-cv-15343; 2:21-cv-02111
- Filed
- 2019-07-12
- Terminated
- 2022-01-28
Patents at issue (5)
Plaintiffs (1)
Summary
Hatch-Waxman ANDA patent-infringement suit involving pomalidomide (ANDA No. 213234). Patents asserted included U.S. 8,198,262, 8,673,939, 8,735,428, 8,828,427, and U.S. 9,993,467. A consent judgment enjoined Dr. Reddy's from infringing the patents-in-suit until expiration and dismissed all claims, counterclaims, and defenses with prejudice.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
In the news
What the press has reported about this case, summarized with links to the source articles.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).